Hikma Pharmaceuticals PLC announced that Siggi Olafsson has resigned as Chief Executive Officer, and from Hikma's Board of Directors, to pursue other opportunities. Said Darwazah, the company's Executive Chairman and former CEO, will assume all CEO responsibilities, enabling the company to continue delivering its strategy. Siggi will remain available to the Group until he departs on 24 June 2022.

Said will continue to work closely with the Executive Committee, including the company's three divisional presidents, benefiting from their significant experience and strong management teams. Concurrently, the company's Board has initiated an externally facilitated process to identify a new CEO.